Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Saußele

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Lancet (London, England)|August 23, 2021
Chronic myeloid leukaemiaJorge Cortes, Carolina Pavlovsky, Susanne Saußele
Oncology Research and Treatment|March 27, 2022
Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data AnalysisSusanne Saußele, Katharina Kohlbrenner, Tobias Vogelmann, et al.
Leukemia|September 19, 2023
Survival with chronic myeloid leukaemia after failing milestonesMichael Lauseker, Rüdiger Hehlmann, Andreas Hochhaus, et al.
Best Practice & Research. Clinical Haematology|November 15, 2016
Management of CML-blast crisisRüdiger Hehlmann, Susanne Saußele, Astghik Voskanyan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Reply to H. Kantarjian et alRüdiger Hehlmann, Joerg Hasford, Markus Pfirrmann, et al.
Leukemia|August 23, 2022
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)Rüdiger Hehlmann, Michael Lauseker, Astghik Voskanyan, et al.
Ejhaem|December 5, 2022
A new aberrantly spliced <i>BCR-ABL1</i> transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemiaNicole Naumann, Ulrike Bross-Bach, Wolfgang Seifarth, et al.
Oncology Research and Treatment|September 25, 2023
[Therapiesteuerung in der Hämatologie und Onkologie]C Benedikt Westphalen, Bernd J Krause, Markus Schuler, et al.
Plos One|April 25, 2018
The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemiaBirgit Spiess, Nicole Naumann, Norbert Galuschek, et al.
Acta Haematologica|May 5, 2025
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trialPhilipp le Coutre, Andreas Burchert, Susanne Saußele, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Lancet (London, England)|August 23, 2021
Chronic myeloid leukaemiaJorge Cortes, Carolina Pavlovsky, Susanne Saußele
Oncology Research and Treatment|March 27, 2022
Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data AnalysisSusanne Saußele, Katharina Kohlbrenner, Tobias Vogelmann, et al.
Leukemia|September 19, 2023
Survival with chronic myeloid leukaemia after failing milestonesMichael Lauseker, Rüdiger Hehlmann, Andreas Hochhaus, et al.
Best Practice & Research. Clinical Haematology|November 15, 2016
Management of CML-blast crisisRüdiger Hehlmann, Susanne Saußele, Astghik Voskanyan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Reply to H. Kantarjian et alRüdiger Hehlmann, Joerg Hasford, Markus Pfirrmann, et al.
Leukemia|August 23, 2022
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)Rüdiger Hehlmann, Michael Lauseker, Astghik Voskanyan, et al.
Ejhaem|December 5, 2022
A new aberrantly spliced <i>BCR-ABL1</i> transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemiaNicole Naumann, Ulrike Bross-Bach, Wolfgang Seifarth, et al.
Oncology Research and Treatment|September 25, 2023
[Therapiesteuerung in der Hämatologie und Onkologie]C Benedikt Westphalen, Bernd J Krause, Markus Schuler, et al.
Plos One|April 25, 2018
The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemiaBirgit Spiess, Nicole Naumann, Norbert Galuschek, et al.
Acta Haematologica|May 5, 2025
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trialPhilipp le Coutre, Andreas Burchert, Susanne Saußele, et al.
Pageof 3